Is a complete CRBP research report available?

No complete published report is available for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NASDAQ: CRBP · USD

$9.05

+0.13 (+1.5%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CRBP analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	167.7M
Net income (ttm)	-84.5M
EPS (ttm)	-$5.66
Shares out	18.5M
Volume	138,831
Beta	2.56
Price target	$35.3	+290.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -84.5M
EPS (ttm): -$5.66
Market cap: 167.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CRBP indicators

Market & fundamental data

Available fields

187

Groups with data

Currency

USD

Showing 187 of 187 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001595097
Company name	Corbus Pharmaceuticals Holdings, Inc.
Country	United States
Country code	US
Cusip	21833P301
Employees	36
Employees Change	8%
Employees Change Percent	28.57
Enterprise value	$30.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US21833P3010
Last refreshed	2026-07-31
Market cap	$167.7M
Market cap category	Micro-Cap
Price	$9.05
Price currency	USD
Sector	Healthcare
Sector PE	45.51
Sector PE Fwd	24.23
Sic	2834
Symbol	CRBP
Website	https://www.corbuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-50.41%
EV Sales Forward	27.6x
FCF yield	-43.93%
P/B ratio	1.27x
PS Forward	150.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-74.3M
Net Income	$-84.5M
Net Income Growth Years	0%
Profit Per Employee	$-2.3M
ROA	-39.48
Roa5y	-36.78
ROCE	-71.11
ROE	-66.7
Roe5y	-123.7
ROIC	-43.61

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-19.89%
Cagr1y	-2.37%
Cagr3y	11.09%
Cagr5y	-26.44%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$144.5M
Cash	$138.2M
Current Assets	$143.6M
Current Liabilities	$18.1M
Debt	$1.2M
Debt Equity	$0.01
Equity	$126.3M
Liabilities	$18.1M
Long Term Assets	$914,000
Long Term Liabilities	$0
Net Cash	$137M
Net Cash By Market Cap	$81.71
Net Cash Growth	5.45%
Net Debt Equity	$-1.08
Tangible Book Value	$126.3M
Tangible Book Value Per Share	$7.12
WACC	18.17

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.92
Net Working Capital	$-11.6M
Quick ratio	7.7
Working Capital	$125.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-25.7%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-89.11%
1Y total return	-2.37%
200-day SMA	9.84
3Y total return	37.12%
50-day SMA	8.7
50-day SMA vs 200-day SMA	50under200
5Y total return	-78.45%
All Time High	323.4
All Time High Change	-97.2%
All Time High Date	2016-10-10
All Time Low	2.11
All Time Low Change	328.91%
All Time Low Date	2023-03-10
ATR	0.51
Beta	2.56
Beta1y	0.64
Beta2y	1.54
Ch YTD	11.18
High	9.36
High52	20.56
High52 Date	2025-10-20
High52ch	-55.98%
Low	8.79
Low52	7.12
Low52 Date	2026-06-02
Low52ch	27.11%
Ma50ch	4.07%
Price vs 200-day SMA	-8.01%
RSI	51.1
RSI Monthly	43.56
RSI Weekly	48.22
Sharpe ratio	0.33x
Sortino ratio	0.53
Total Return	-25.7%
Tr YTD	11.18
Tr1m	0.78%
Tr1w	-2.9%
Tr3m	-7.84%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	8
Analyst Price Target Top	$37.57
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.25
Operating Income	$-89.8M
Price target	$35.3
Price Target Change	$290
Price Target Change Top	$315

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14,320,081%
Float Percent	77.29%
Shares Insiders	0.68%
Shares Institutions	52.53%
Shares Out	18,527,795
Shares Qo Q	13.49%
Shares Yo Y	25.7%
Short Float	14.64%
Short Ratio	4.54
Short Shares	11.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-80.1M
Adjusted OCF	-80,131,000
Average Volume	288,462.15x
Bv Per Share	7.12
CAPEX	$-13,000
Ch10y	-89.11
Ch1m	0.78
Ch1w	-2.9
Ch1y	-2.37
Ch3m	-7.84
Ch3y	37.12
Ch5y	-78.45
Ch6m	4.87
Change	1.46%
Change From Open	1.69
Close	8.92
Days Gap	-0.22
Depreciation Amortization	201,000
Dollar Volume	1,256,420.6
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-89.8M
EBITDA	$-89.6M
EPS	$-5.66
F Score	1
FCF	$-73.7M
FCF EV Yield	-240.21x
FCF Per Share	$-3.98
Financing CF	77,426,000
Fiscal Year End	December
Founded	2,009
Investing CF	2,691,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Date	2023-02-14
Last Split Type	Reverse
Last10k Filing Date	2026-03-09
Ma150	8.94
Ma150ch	1.19%
Ma20	9.14
Ma20ch	-0.95%
Net CF	6,476,000
Next Earnings Date	2026-08-11
Open	8.9
Optionable	Yes
Position In Range	45.61
Post Close	9.05
Postmarket Change Percent	1.99
Postmarket Price	$9.23
Ppne	914,000
Price Date	2026-07-30
Ptbv Ratio	1.33
Relative Volume	0.48x
Share Based Comp	6,490,000
Tr6m	4.87%
Us State	Massachusetts
Volume	138,831

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Coverage state: Market snapshot only — no published research

Generate the first CRBP analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CRBP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CRBP indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CRBP

Frequently asked questions